Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population

Completed

• Conditions: Gastrointestinal Disease

• Registration Number: NCT03118778
• Lead Sponsor: AstraZeneca

Brief Summary

This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.

Detailed Description

Study primary objective is to identify the inappropriate use of PPI (overall, outpatient \& inpatient).

Study Timeline

• Study First Submitted: 2017-04-13
• Study First Submitted QC: 2017-04-13
• Study First Posted: 2017-04-18
• Study Start: 2017-04-28
• Primary Completion: 2017-07-10
• Study Completion: 2017-07-10
• Status Verified: 2018-06
• Last Update Submitted: 2018-07-11
• Last Update Posted: 2018-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 90895

Inclusion Criteria

• All patients in 2015 China Health Insurance Research Association (CHIRA) database.
• Patients had PPI prescription during Jan. 2015 to Dec. 2015 will be selected to estimate the PPI inappropriate use.

Exclusion Criteria

• Patients without data of treatment information.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall proportion of patient inappropriate use of PPI	2015.01-2015.12	Overall number of patient times/courses with PPI inappropriate use (including non-indication use, over maximum daily dose and over maximum duration) divided by the total number of patient-times/courses with PPI use for both outpatients and inpatients.

Trial Locations

Locations (1)

Research Site; 🇨🇳 Beijing, China